openPR Logo
Press release

Beta Thalassemia Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Roche, Agios Pharma, Vertex Pharma, Pharmacosmos, Editas Medicine, HemaQuest Pharma, Acceleron Pharma

11-02-2023 06:13 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Beta Thalassemia Market to Observe Impressive Growth During

DelveInsight's "Beta Thalassemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Beta Thalassemia, historical and forecasted epidemiology as well as the Beta Thalassemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Beta Thalassemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Beta Thalassemia Market Forecast
https://www.delveinsight.com/sample-request/beta-thalassemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Beta Thalassemia Market Report:
• The Beta Thalassemia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In September 2023, Pharmacosmos has initiated aPhase IItrial ofSP-420 in patients with transfusion-dependent β-thalassemia.
• In June 2023, FDA accepted the Biologics License Application (BLAs) of exagamglogene autotemcel (exa-cel) for transfusion dependent beta thalassemia (TDT). The Prescription Drug User FeeAct (PDUFA) target action date for TDT is March 30, 2024.
• The Centers for Disease Control and Prevention (2023) state that beta thalassemia is comparatively uncommon in the US
• According to Forni et al. (2023), there has been a rise in prevalence in the US. The incidence of β-thalassemia has increased by 7.5% in the United States over the past 50 years, in part because of immigration and adoption from Middle Eastern and Asian nations
• In 2022, it was discovered that there were approximately 3,000 cases of beta thalassemia in the US.
• Italy had the highest prevalence of beta thalassemia among EU4 and the UK, with almost 9,000 cases reported in 2022, while Spain had the lowest number of cases in the same year.
• Key Beta Thalassemia Companies: Agios Pharmaceuticals, Vertex Pharmaceuticals, Pharmacosmos, Editas Medicine, HemaQuest Pharmaceuticals, Acceleron Pharma, Bristol-Myers Squibb, Hoffmann-La Roche, Sanofi, Novartis, EmeraMed, Pharmacosmos A/S, Celgene, DisperSol Technologies, LLC, Agios Pharmaceuticals, Shire, and others
• Key Beta Thalassemia Therapies: PYRUKYND (mitapivat), CTX001, SP-420, EDIT-301, dimethylbutyrate, ACE-536, Luspatercept, Bitopertin, Deferitrin (GT56-252), ICL670, Emeramide, SP-420, Luspatercept, DST-0509, Mitapivat, SPD602, and others
• The Beta Thalassemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Beta Thalassemia pipeline products will significantly revolutionize the Beta Thalassemia market dynamics.

Beta Thalassemia Overview
Reduced synthesis of hemoglobin subunit beta (hemoglobin beta chain) is the hallmark of beta thalassemia (β-thalassemia), a blood disorder that causes reduced amounts of hemoglobin A (HbA) on hemoglobin analysis, an abnormal peripheral blood smear with nucleated red blood cells, and microcytic hypochromic anemia.

Get a Free sample for the Beta Thalassemia Market Report
https://www.delveinsight.com/report-store/beta-thalassemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Beta Thalassemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Beta Thalassemia Epidemiology Segmentation:
The Beta Thalassemia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Beta Thalassemia
• Prevalent Cases of Beta Thalassemia by severity
• Gender-specific Prevalence of Beta Thalassemia
• Diagnosed Cases of Episodic and Chronic Beta Thalassemia

Download the report to understand which factors are driving Beta Thalassemia epidemiology trends @ Beta Thalassemia Epidemiology Forecast
https://www.delveinsight.com/sample-request/beta-thalassemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Beta Thalassemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Beta Thalassemia market or expected to get launched during the study period. The analysis covers Beta Thalassemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Beta Thalassemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Beta Thalassemia Therapies and Key Companies
• PYRUKYND (mitapivat): Agios Pharmaceuticals
• CTX001: Vertex Pharmaceuticals
• SP-420: Pharmacosmos
• EDIT-301: Editas Medicine
• dimethylbutyrate: HemaQuest Pharmaceuticals
• ACE-536: Acceleron Pharma
• Luspatercept: Bristol-Myers Squibb
• Bitopertin: Hoffmann-La Roche
• Deferitrin (GT56-252): Sanofi
• ICL670: Novartis
• Emeramide: EmeraMed
• SP-420: Pharmacosmos A/S
• Luspatercept: Celgene
• DST-0509: DisperSol Technologies, LLC
• Mitapivat: Agios Pharmaceuticals
• SPD602: Shire

Discover more about therapies set to grab major Beta Thalassemia market share @ Beta Thalassemia Treatment Market
https://www.delveinsight.com/sample-request/beta-thalassemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Beta Thalassemia Market Strengths
• Strong pipeline activity with potential Phase III and phase II emerging therapies.
• Increasing prevalence and awareness of beta thalassemia

Beta Thalassemia Market Opportunities
• Lack of any curative treatment options despite the launch of gene therapies which are subject to patient outcome assessment
• Improved national blood policies
• Advancement in genetic engineering because gene therapy has been hypothesized to serve as an effective cure for monogenic blood disorders for several decades

Scope of the Beta Thalassemia Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Beta Thalassemia Companies: Agios Pharmaceuticals, Vertex Pharmaceuticals, Pharmacosmos, Editas Medicine, HemaQuest Pharmaceuticals, Acceleron Pharma, Bristol-Myers Squibb, Hoffmann-La Roche, Sanofi, Novartis, EmeraMed, Pharmacosmos A/S, Celgene, DisperSol Technologies, LLC, Agios Pharmaceuticals, Shire, and others
• Key Beta Thalassemia Therapies: PYRUKYND (mitapivat), CTX001, SP-420, EDIT-301, dimethylbutyrate, ACE-536, Luspatercept, Bitopertin, Deferitrin (GT56-252), ICL670, Emeramide, SP-420, Luspatercept, DST-0509, Mitapivat, SPD602, and others
• Beta Thalassemia Therapeutic Assessment: Beta Thalassemia current marketed and Beta Thalassemia emerging therapies
• Beta Thalassemia Market Dynamics: Beta Thalassemia market drivers and Beta Thalassemia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Beta Thalassemia Unmet Needs, KOL's views, Analyst's views, Beta Thalassemia Market Access and Reimbursement

To know more about Beta Thalassemia companies working in the treatment market, visit @ Beta Thalassemia Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/beta-thalassemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Beta Thalassemia Market Report Introduction
2. Executive Summary for Beta Thalassemia
3. SWOT analysis of Beta Thalassemia
4. Beta Thalassemia Patient Share (%) Overview at a Glance
5. Beta Thalassemia Market Overview at a Glance
6. Beta Thalassemia Disease Background and Overview
7. Beta Thalassemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Beta Thalassemia
9. Beta Thalassemia Current Treatment and Medical Practices
10. Beta Thalassemia Unmet Needs
11. Beta Thalassemia Emerging Therapies
12. Beta Thalassemia Market Outlook
13. Country-Wise Beta Thalassemia Market Analysis (2019-2032)
14. Beta Thalassemia Market Access and Reimbursement of Therapies
15. Beta Thalassemia Market Drivers
16. Beta Thalassemia Market Barriers
17. Beta Thalassemia Appendix
18. Beta Thalassemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Beta Thalassemia Pipeline https://www.delveinsight.com/report-store/beta-thalassemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Beta Thalassemia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Beta Thalassemia market. A detailed picture of the Beta Thalassemia pipeline landscape is provided, which includes the disease overview and Beta Thalassemia treatment guidelines.
Beta Thalassemia Epidemiology https://www.delveinsight.com/report-store/beta-thalassemia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Beta Thalassemia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Beta Thalassemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of heart failure and cardiovascular diseases due to obesity, age, & unhealthy lifestyles and rising demand for organ transplants due to increasing prevalence of chronic ailments such as hypertension, diabetes, and others

B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Beta Thalassemia Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Roche, Agios Pharma, Vertex Pharma, Pharmacosmos, Editas Medicine, HemaQuest Pharma, Acceleron Pharma here

News-ID: 3274333 • Views:

More Releases from DelveInsight Business Research

DelveInsight Unveils Comprehensive Epidemiology Assessment of Cutaneous Squamous Cell Carcinoma (cSCC) Across 15 Countries
DelveInsight Unveils Comprehensive Epidemiology Assessment of Cutaneous Squamous …
DelveInsight, a global leader in healthcare research and analytics, announces the release of its in-depth Cutaneous Squamous Cell Carcinoma (cSCC) Epidemiology Assessment, providing unparalleled insights into the prevalence of cSCC among solid organ transplant recipients across 15 countries, including the United States, key European nations, and select countries in the Asia-Pacific (APAC) region. The newly released assessment delivers country-specific epidemiological insights aimed at guiding strategic decision-making for pharmaceutical companies, healthcare providers,
Unlocking Market Potential: DelveInsight's Comprehensive Patent Foramen Ovale (PFO) Device Landscape Analysis Empowers Strategic Market Entry in the EU
Unlocking Market Potential: DelveInsight's Comprehensive Patent Foramen Ovale (P …
DelveInsight's Market Size & Forecast Assessment Provides Data-Driven Insights for Patient-Centric Market Expansion Strategies DelveInsight, a leading healthcare market research and consulting firm, has released an in-depth case study highlighting its latest assessment of the Patent Foramen Ovale (PFO) Device Market across the European Union. This strategic market intelligence report provides a holistic understanding of the patient population, device market size, competitor landscape, and reimbursement scenario, equipping medical device companies with
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market Poised for Robust Growth at 6.35% CAGR through 2032, States DelveInsight
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market Poised for …
The Chronic Obstructive Pulmonary Disease (COPD) Treatment Devices Market is set for strong expansion, projected to grow at a CAGR of 6.35% from 2025 to 2032, according to recent industry findings. This growth is primarily fueled by the increasing global prevalence of COPD, escalating exposure to tobacco smoke and air pollution, expanding screening programs, and the rapid development of next-generation respiratory devices such as portable nebulizers and smart inhalers. The global
CD40 Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight
CD40 Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, CD40 pipeline constitutes key companies continuously working towards developing CD40 treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "CD40 Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CD40 Market. The CD40 Pipeline report embraces in-depth commercial and

All 5 Releases


More Releases for Beta

Beta-lactam and Beta-lactamase Inhibitors Market Emerging Trends and Growth Pros …
The global beta-lactam and beta-lactamase inhibitors market is valued at approximately $60 billion in 2024, driven by the rising prevalence of bacterial infections and the increasing resistance to traditional antibiotics. The market is projected to reach around $85 billion by 2034, reflecting a robust growth trajectory. This results in a Compound Annual Growth Rate (CAGR) of approximately 6.5% during the forecast period of 2025-2034. Exactitude Consultancy., Ltd. released a research report
Beta-Lactams & Beta-Lactamase Inhibitors: A Persistent Powerhouse in the Antibio …
The antibiotics market, despite facing challenges, remains a critical sector in global healthcare. Within this landscape, the Beta-Lactam and Beta-Lactamase Inhibitor segment stands out as a high-opportunity area, driven by the continued prevalence of bacterial infections and the ongoing fight against antimicrobial resistance (AMR). Market Dynamics and Growth Drivers Beta-lactam antibiotics, including penicillins and cephalosporins, have been the cornerstone of antibacterial therapy for decades. Their broad spectrum of activity and generally favorable
apuem - beta
Today the beta phase of apuem starts. Our goal is to create the largest web app collection, and for that we need your help. So if you know a useful online tool that you like to use, suggest it to us. See more: apuem.com/suggestions We appreciate any kind of participation. Thank you very much! Apuem Finkenhofstraße 27 60322 Frankfurt am Main Germany Jacob Kearson support@apuem.com More Information: apuem.com/contact We and our community search for the best web apps
Beta-lactam and Beta-lactamase Inhibitors Market to Reach $34,170 Million by 202 …
Global beta-lactam and beta-lactamase inhibitors market size was $27,126 million in 2018, and is projected to reach $34,170 million by 2028, growing at a CAGR of 2.3% from 2019 to 2028. The cephalosporin segment accounted more than two-fifths of the total beta-lactam and beta-lactamase inhibitors market share in 2018. Download Report Sample PDF @ https://www.alliedmarketresearch.com/request-sample/5427 Beta-lactam and beta-lactamase inhibitors are chemical compounds of natural or semi-synthetic or synthetic origin. They inhibit
Beta-lactam and Beta-lactamase Inhibitors Market Outlook from 2019 to 2028
"According to a new report published titled, ""India Heat Exchangers Market by Type, Material of Construction, and End-User Industry: Opportunity Analysis and Industry Forecast, 2019-2026,"" the India heat exchangers market accounted for revenue of $454.4 million in 2018, and is anticipated to generate $890.0 million by 2026. The market is projected to grow at a CAGR of 8.6% from 2019 to 2026. Heat exchangers are devices that transfer energy between fluids
Beta-lactam and Beta-lactamase Inhibitors Market Size, Share, Development by 202 …
Global Info Research offers a latest published report on Beta-lactam and Beta-lactamase Inhibitors Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Beta-lactam and Beta-lactamase Inhibitors players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Beta-lactam and Beta-lactamase